Over the last 24 months, there has been growing evidence of a correlation between mRNA
COVID-19 vaccine boosters and increased prevalence of COVID-19 infection and other …

Introduction Anti-spike monoclonal antibodies were highly effective for prophylaxis and early
treatment of mild-to-moderate COVID-19 in high-risk populations. Areas covered This article …

Methods| The primary data source was the Centers for Disease Control and Prevention
National Healthcare Safety Network (NHSN) Nursing Home COVID-19 database, which …

Background COVID-19 severity is associated with its respiratory manifestations. Neutralising
antibodies against SARS-CoV-2 administered systemically have shown clinical efficacy …

Background: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide
analogue inhibits SARS-CoV-2 replication in vitro. Materials & methods: Adults in hospital …

Monoclonal antibodies (mAbs) are effective therapeutic agents against many acute
infectious diseases including COVID‐19, Ebola, RSV, Clostridium difficile, and Anthrax …

The emergence of novel mutations in the SARS‐CoV‐2 spike protein challenges
monoclonal antibody (mAb) effectiveness. Comprehending resistance mutations and …

As a class of antibodies that specifically bind to a virus and block its entry, neutralizing
monoclonal antibodies (neutralizing mAbs) have been recognized as a top choice for …

The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate
the impact of COVID-19 pandemic. The present study examines the strategic application of …

Abstract Coronavirus disease 2019 (COVID-19) epidemiology and product landscapes have
changed considerably since onset of the pandemic. Safe and effective vaccines and …